Login

Lost your password?
Don't have an account? Sign Up

We are a regional biopharmaceutical enterprise that stands at the forefront of scientific innovation. We are dedicated to harnessing cutting-edge technologies in the fields of immunology and regenerative medicine to reshape the future of healthcare.

At All Life, we are pioneers in cellular engineering. Our ground-breaking achievements in

• Induced Pluripotent Stem Cells (iPSC) reprogramming and
• Chimeric Antigen Receptor (CAR)

technologies and advancements are not only transforming the medical landscape but also creating healthcare solutions that benefit both the medical and general communities.

ALL LIFE MEDICALS
SCIENCE & TECHNOLOGY
CO. LTD

Yunnan Tumor Hospital Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Kunming University of Science & Technology, Kunming, China
Henan Provincial People’s Hospital, Zhengzhou, Henan, China
Peking University, Beijing, China
Peking Union Medical College Hospital, Beijing, China
Beijing Cancer Hospital, Beijing, China

ALL LIFE Advanced
IMMUNOLOGY
SDN. BHD.

ALL LIFE
BIO TECHNOLOGY
SDN. BHD.

CORE RESEARCHERS

Supported by 120+
In-house Scientists

• RESEARCH

• CLINICAL

• APPLICATIONS DEVELOPMENT

• COMMERCIALIZATION

CORE RESEARCHERS

clinical trials

OVARIAN CANCER

COLORECTAL CANCER

PROSTATE CANCER

LEUKEMIA

B CELL LYMPHOMA

MULTIPLE MELOMA

LOU GEHRIG’S DISEASE (ALS)

PARKINSON

BRAIN & SPINAL CORD INJURY

ISCHEMIC STROKE

TYPE 1 - DIABETES

CAR-NK Research & Clinical Trials

CAR-NK Patent (China) NO.: 20190209997.5

LUNG

COLORECTAL

OVARIAN

LEUKEMIA

BREAST

PROSTATE

LIVER

PANCREATIC

Research and Clinical Trial Status

Cell
Source

Medical
Conditions

R & D /
Preclinical

Phase I /
RF 1

Phase II

Phase III

Anti-CD19 CAR-NK

Leukemia

NCT03690310

Anti-CD22 CAR-NK

Leukemia

NCT03692767

Anti-CD19/
CD22 CAR-NK

Leukemia

NCT03824964

Anti-MSLN CAR-NK

Ovarian Cancer

NCT03692637

Anti-PSMA CAR-NK

Prostate Cancer

NCT03692663

CD19 iCAR-NK

Leukemia

NCT03824951

CAR-NK TECHNOLOGY

Immunotherapy pipeline

Product

Indications

Research

Preclinical

I/II Clinical

ALLLIFE CAR-NK CD19

Acute B Leukemia (ALL)

ALLLIFE CAR-NK BCMA

Multiple Myeloma (MM)

ALLLIFE CAR-NK PMSA

Prostatic Cancer

ALLLIFE CAR-NK Meso

Ovarian Cancer

Induced Pluripotant Stem Cell (iPSC) Research &
Clinical Trials

Manipulation of differentiated cells into specific functional cells.
Restore natural function of affected tissues and organs.
Replace lost, damaged, or diseased cells, tissues, and/or organs.
Personalized therapy for treatment of debilitating and rare diseases.

Research and Clinical Trial Status

Cell
Source

Medical
Conditions

R & D /
Preclinical

Phase I /
RF 1

Phase II

Phase III

iISLET

Diabetes Type 1

NCT03728296

iWPC

Ischemic Stroke

NCT03726814

iNSC

Ischemic Stroke7

NCT03725865

iNSC

Parkinson’s

NCT03815071

iNSC

Thalassemia

NCT03728322

iRPE

Age-related macular degeneration (AMD)

NCT03559764

IPSC REPROGRAMMING

Induced Pluripotent Stem Cells (iPSC) derived pipeline

Product

Applications

Research

Preclinical

I/II Clinical

Hematopoietic Stem Cells (iHSC)

Fabry/Thalassemia

Neuron Stem Cells (iNSC)

ALS

Islet Cells (iISLET)

Diabetes/Demyelination

Endothelial Progenitor Cells (iEPC)

Heart Failures

Hematopoietic Stem Cells (iHSC)

Transplantation/Blood Cancers

Neuron Stem Cells (iNSC)

Parkinson’s/Ischemic Stroke

PRODUCTS

PRODUCTS

Mesenchymal Stem Cells (MSC)
MSC (Passage 2) :
P(2) Premium One & P(2) Premium

100.0 million cells: Medical & General Wellness.

MSC (Passage 5) : MSC+

100.0 million cells: Medical & General Wellness.

50.0 million cells: Medical & General Wellness.

25.0 million cells: Medical

PRODUCTS

Natural Killer Cells & T cells
(Autologous): NK+

1.0 billion cells: Medical & General Wellness

4.0 billion cells: Medical & General Wellness

10.0 billion cells: Medical

Natural Killer Cells (Allogenic): NK-C

1.0 billion cells: Medical & General Wellness

4.0 billion cells: Medical & General Wellness

10.0 billion cells: Medical

Cytokine Induced Killer Cells (CIK)

1.0 billion cells: Medical

4.0 billion cells: Medical

10.0 billion cells: Medical

PRODUCTS

Exosome

MX-18: Aesthetic

ExoHealth: Medical & General Wellness

ExoMed: Medical & General Wellness

NeuroMed: Medical & General Wellness (Testing)

PRODUCTS

Cord Blood Plasma

PS-16 (Autologous): Aesthetic

PS-18 (Allogenic): Aesthetic

PRODUCTS

SERVICES

Original Bio-Manufacturer

We rely on the latest high-tech manufacturing equipment and dedicated professional staff who are operational in both R&D and manufacturing. We provide a full range of product development services, from production of raw materials for formulation to packaging and design as well as consultation services.

Customized Therapy

The challenge we face today is the threat to our quality-of-life brought on by diseases, which are caused by ‘diseased’ cells, whereby current available treatment options are merely treating or managing the symptoms of these diseases. We are at the forefront in cellular reprogramming and NK-based engineering technologies. Depending on the age of the patient, type of disease, malignancy, stage, and status of the disease, we work with highly-skilled and trained medical professionals to develop and design innovative, accessible solutions using our technological assets to deliver customized therapies for each unique individual.

Customized Product Formulation

Custom formulation is the creation of a product made exclusively for you or your company based on your specifications. If you are looking for an exclusive formula for your product and do not have an in-house product development team, look no further, we at ALL LIFE can assist.

Our state-of-the art GMP certified laboratory and highly experienced team of scientists utilize advanced technologies and delivery systems to formulate an exclusive product just for you. If you have a concept in mind for a customized product our knowledgeable R&D team can assist in creating a unique formulation tailored exactly to your specifications, resulting in a profitable product suited to appeal to your target demographic.

All life talk series

Video board

CONTACT US

    info@alllifegroup.com
    Customer service: +(603) 7863 9888

    Copyright © 2022 ALL LIFE ADVANCED IMMUNOLOGY SDN BHD 201701021857 (1236023-V). All Rights Reserved

    TERMS OF USE | PRIVACY POLICY

    We are a regional biopharmaceutical enterprise that stands at the forefront of scientific innovation. We are dedicated to harnessing cutting-edge technologies in the fields of immunology and regenerative medicine to reshape the future of healthcare.

    At All Life, we are pioneers in cellular engineering. Our ground-breaking achievements in

    • Induced Pluripotent Stem Cells (iPSC) reprogramming and
    • Chimeric Antigen Receptor (CAR)

    technologies and advancements are not only transforming the medical landscape but also creating healthcare solutions that benefit both the medical and general communities.

    ALL LIFE MEDICALS SCIENCE & TECHNOLOGY CO. LTD

    Yunnan Tumor Hospital Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
    Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
    Kunming University of Science & Technology, Kunming, China
    Henan Provincial People’s Hospital, Zhengzhou, Henan, China
    Peking University, Beijing, China
    Peking Union Medical College Hospital, Beijing, China
    Beijing Cancer Hospital, Beijing, China

    ALL LIFE Advanced
    IMMUNOLOGY
    SDN. BHD.

    ALL LIFE
    BIO TECHNOLOGY
    SDN. BHD.

    CORE
    RESEARCHERS

    Supported by 120+
    In-house Scientists

    • RESEARCH

    • CLINICAL

    • APPLICATIONS DEVELOPMENT

    • COMMERCIALIZATION

    CORE RESEARCHERS

    CLINICAL
    TRIALS

    OVARIAN CANCER

    COLORECTAL CANCER

    PROSTATE CANCER

    LEUKEMIA

    B CELL LYMPHOMA

    MULTIPLE MELOMA

    LOU GEHRIG’S DISEASE (ALS)

    PARKINSON

    BRAIN & SPINAL CORD INJURY

    ISCHEMIC STROKE

    TYPE 1 - DIABETES

    CAR-NK Research & Clinical Trials

    CAR-NK Patent (China) NO.: 20190209997.5

    LUNG

    COLORECTAL

    OVARIAN

    LEUKEMIA

    BREAST

    PROSTATE

    LIVER

    PANCREATIC

    Research and Clinical Trial Status

    Cell Source : Anti-CD19 CAR-NK

    Medical Conditions: Leukemia

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03690310

    Cell Source : Anti-CD22 CAR-NK

    Medical Conditions: Leukemia

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03692767

    Cell Source : Anti-CD19/CD22 CAR-NK

    Medical Conditions: Leukemia

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03824964

    Cell Source : Anti-MSLN CAR-NK

    Medical Conditions: Ovarian Cancer

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03692637

    Cell Source : Anti-PSMA CAR-NK

    Medical Conditions: Prostate Cancer

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03692663

    Cell Source : CD19 iCAR-NK

    Medical Conditions: Leukemia

    R & D /Preclinical

    Phase I /RF 1

    Phase II

    Phase III

    NCT03824951

    CAR-NK TECHNOLOGY

    Induced Pluripotant Stem Cell (iPSC) Research &
    Clinical Trials

    Manipulation of differentiated cells into specific functional cells.
    Restore natural function of affected tissues and organs.